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Abstract Elevated serum levels of the phosphate-regu-
lating hormone ﬁbroblast growth factor 23 (FGF23) are
found in patients with phosphate wasting diseases and
chronic kidney disease-mineral and bone disorder (CKD-
MBD). These diseases are associated with rickets and renal
osteodystrophy, respectively. FGF23 is secreted from
osteoblastic cells and signals through FGFRs, membrane
coreceptor alpha-Klotho (Klotho), and, possibly, a circu-
lating form of Klotho. Despite the absence of detectable
Klotho on osteoblastic cells, studies have suggested that
forced FGF23 expression in osteoblasts inhibited mineral-
ization. Thus, we examined the effects of exogenously
applied FGF23 on osteoblastic MC3T3.E1 cell prolifera-
tion and differentiation, with and without soluble Klotho.
MC3T3.E1 cells were cultured in osteoblast differentiation
medium, supplemented with FGF23 (0.1–1,000 ng/mL),
Klotho (50 ng/mL), the combination FGF23 ? Klotho,
and FGF2 (100 ng/mL) as a control. Neither FGF23 nor
Klotho exposure affected proliferation of day 4 growth
phase cells or mineralization of day 14 cultures. In contrast,
FGF23 ? Klotho resulted in inhibition of mineralization
and osteoblast activity markers at day 14, and a slight,
reproducible induction of proliferation. Inhibition of
FGFR1, but not FGFR2 or FGFR3, completely restored
FGF23 ? Klotho-induced inhibition of alkaline phospha-
tase (ALP) activity at day 7. ALP activity was partially
restored by the MAPK inhibitor U0126 but not inhibitors
p38 and P13K. Thus, soluble Klotho enables FGF23 sig-
naling in MC3T3.E1 cells, likely through FGFR 1(IIIc).
Elevated FGF23 actions, in part, appear to parallel FGF2
with lower potency. In addition to affecting bone via
indirect phosphate wasting pathways, supraphysiological
FGF23 and soluble Klotho may directly impact bone in
diseases with elevated FGF23 levels.
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Fibroblast growth factor 23 (FGF23) is a phosphate-regu-
lating hormone synthesized primarily in osteoblast lineage
cells in bone and secreted into the circulation [1]. FGF23
acts by preventing the reabsorption of phosphate from the
renal tubule, leading to increased phosphate excretion,
and by limiting dietary absorption of phosphate through
inhibition of renal 25-hydroxyvitamin D3,1 a-hydroxylase
(1aOHase) [2–7]. In diseases associated with phosphate
imbalance, serum levels of FGF23 are pathologically
altered with elevations in phosphate wasting diseases, such
as autosomal-dominant hypophosphatemic rickets (ADHR)
[8], X-linked hypophosphatemic rickets (XLH) and tumor-
induced osteomalacia (TIO) [9, 10], and autosomal-reces-
sive hypophosphatemic rickets (ARHR) [11], as well as
deﬁciencies in diseases of phosphate retention, such as
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with secondary hyperparathyroidism (HPT) often have
serum FGF23 levels several thousandfold higher than
healthy individuals [3, 4, 7].
The elevated serum FGF23 levels in chronic kidney
disease-mineral and bone disorder (CKD-MBD) patients
may represent a compensatory response to increased serum
phosphorus load due to kidney failure. However, in addition
to sustained dietary phosphate load, FGF23 is upregulated
by regulators of bone metabolism, including 1,25-di-
hydroxyvitamin D3 (1,25[OH]2D3)[ 13] and parathyroid
hormone (PTH) [14], which are known to be altered in
patients with CKD-MBD. It is well appreciated that sus-
tained hormonal and mineral imbalances in patients with
CKD contribute to the development of renal osteodystrophy
(ROD), a severe bone disorder [15]. A signiﬁcant amount of
data indicates that alterations in PTH contribute to the dis-
ease process, whereas the role of FGF23 in the pathogenesis
of CKD-MBD is much less clear. Others have demonstrated
that FGF23 expression is increased in bone of a CKD-MBD
rodent model [16]. Further, FGF23 in serum from patients
withadvancedCKD-MBDondialysiswasfoundtobeintact
and biologically active [17], suggesting that circulating
FGF23inCKD-MBDpatientsimpactstissuesexpressingthe
appropriate receptors.
FGF23 is a member of the endocrine FGF19 family,
which, like other FGFs, signals through FGF receptors
(FGFRs) [18, 19]. However, due to its atypical heparin
binding domain, FGF23 binds FGFRs with low afﬁnity
[19], except in the presence of the coreceptor alpha-Klotho
(Klotho), which confers high-afﬁnity binding [20]. FGFRs
are encoded by distinct genes—FGFRs 1, 2, 3, and 4—and
each is characterized by a tyrosine kinase intracellular
domain, a transmembrane domain, and three extracellular
immunoglobulin domains (D1–D3). Several isoforms with
different ligand speciﬁcities are generated by alternative
splicing events. A splicing event in FGFRs 1, 2, and 3
excludes exon 8 or 9 in the third immunoglobulin domain
(III) generating FGFR ‘‘c’’ and ‘‘b’’ forms, respectively. In
cells transfected with different FGFRs and Klotho, FGF23
signaling occurred preferentially through the FGFR1(IIIc)
isoform [21], suggesting that FGFR1(IIIc) is the predomi-
nant physiological FGF23 receptor.
Klotho is a single-pass transmembrane protein with a
short intracellular domain found on FGF23 target tissues
(such as kidney and parathyroid glands) [22, 23]. Klotho
contains a short intracellular domain and two extracellular
domains with similarity to glycosidases (KL1 and KL2).
Two circulating forms of Klotho have been described in
mice and humans. These two forms are generated by dif-
ferent processes: one involving an alternative RNA splic-
ing event (to generate a 68-kDa, 549-aa KL1 domain
containing protein) and the other involving a proteolytic
cleavage of cell surface Klotho (to yield predominantly the
entire 130-kDa extracellular KL1- and KL2-containing
domain of Klotho) [24]. The soluble extracellular domain
of Klotho is functional as a coreceptor for FGF23 in vitro,
though it is less active than the membrane form [20].
Despite the absence of detectable Klotho mRNA
expression in bone or bone marrow [23], forced FGF23
expression in rat calvarial cells suggested that supraphysio-
logical FGF23 levels directly inhibit osteoblast mineraliza-
tion [25]. Other studies using cell lines or forced FGFR
expression demonstrated that supraphysiological levels of
FGF23 and heparin/heparin sulfate glycosaminoglycans
inhibitphosphatetransportviathemitogen-activatedprotein
kinase (MAPK) pathway in opossum kidney (OK) epithelial
cells [26] or induced proliferation in FGFR-transfected
murinebonemarrow-derivedpro-B(BaF3)cells[19].These
studies raise the possibility that FGF23 may have an auto-
crine/paracrine effect on osteoblastic cells in bone or other
cells and signal in the absence of membrane Klotho.
To determine the impact of elevated FGF23 (as seen in
patients with CKD-MBD) on MC3T3.E1 cells, which are
derived from mouse calvarial osteoblasts, we examined the
direct effects of FGF23 on MC3T3.E1 proliferation, dif-
ferentiation, and cell signaling pathways in the presence
and absence of soluble Klotho. In addition, we examined
the effects of FGF23 on primary human proximal tubule
epithelial cells (PTECs).
Methods
Cells and Reagents
Renal PTECs and culture medium were obtained from
Lonza Bioscience (Walkersville, MD). Oversulfated hep-
arin (OS-H, GT6020) was purchased from Neoparin
(Alameda, CA). Antibodies for phospho-extracellular sig-
nal-regulated kinase (p-ERK1/2), phospho-p38 (p-p38)
MAPK, and phosphorylated tyrosine (pTYR) were from
Biosource/Invitrogen (Carlsbad, CA); ERK1/2 and p38
were from Upstate Biotech/Millipore (Temecula, CA);
early growth response-1 protein (Egr-1) was from Santa
Cruz Biotechnology (Santa Cruz, CA); and epidermal
growth factor (EGF) was from R&D Systems (Minneapolis,
MN). Human FGF23 wild-type (LO80106, stock concen-
tration 1.7 mg/mL) and mutant R176Q (LO5316, stock
1.6 mg/mL) were made at Amgen (Thousand Oaks, CA).
FGF2 (basicFGF) (lotBUE3108101, stock 100 lg/mL) was
obtained from R&D Systems. The p38 inhibitor SB203580
(PHZ1253, lot 72547179A, stock 50 mg/mL, 132 mM) was
from Invitrogen; the phosphoinositide 3-kinase (P13 K)
inhibitor LY294002 (9901, lot 9, stock 15.3 mg/mL,
50 mM) was from Cell Signaling (Hayward, CA);
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stock 5 mg/mL, 33 lM (ND50 = 0.67–2.7 nM) and FGFR3
neutralizing antibody (MAB710, lot FTD02, stock 5 mg/
mL, 33 lM (ND50 = 20–80 nM) were from R&D Systems.
The FGFR1 tyrosine kinase inhibitor SU 5402 and the
MAPK pathway ERK1/2 inhibitor U0126 were from Sig-
naling Technology (Beverly, MA).
Treatment of Cells
PTECswereculturedon12-or48-wellplatesat1to2 9 10
6
cells/mL in 1 or 0.5 mL, respectively. Cells were typically
B50% conﬂuent at the time of treatments. Cells were
exposed to 0–1,000 ng/mL human FGF23-wild-type or
mutant (huFGF23R176Q) ? OS-H (4 lg/mL) or Klotho
(1 lg/mL).
Western Blot
Treated PTECs were harvested on ice in phosphate-buffered
saline (PBS) and centrifuged. Cell pellets were resuspended
in an appropriate volume of lysis buffer (50 mM Tris–HCl
[pH 7.4], 50 mM NaCl, 5 mM EDTA, 1% Triton X-100,
0.05% SDS, 50 mM NaF, 10 mM b-glycerophosphate,
10 mM sodium pyrophosphate, 100 lM NaVO4, protease
inhibitorcocktail;Roche AppliedScience,Indianapolis,IN)
and sonicated. After centrifugation at 4C, the supernatant
was removed and the protein concentration determined
(BCAproteinassayreagent;Pierce,Rockford,IL).Anequal
amountoftotalproteinofeachsamplewasresolvedbySDS-
PAGE and transferred onto nitrocellulose membrane
(Invitrogen). Blots were blocked for 1 hour in Tris-buffered
saline-Tween (TBST; 20 mM Tris–HCl [pH 7.6], 137 mM
NaCl, 0.1% Tween-20) containing 5% milk (blocking buf-
fer) before incubation with primary antibodies for 2 hours at
room temperature. After three washes with TBST, blots
were incubated with peroxidase-conjugated secondary
antibodies (Amersham/GE Healthcare, Piscataway, NJ).
Antibody binding was detected using enhanced chemilu-
minescence (Amersham/GE Healthcare).
p-ERK1/2 and ERK1/2 Detection
PTECs grown in 12-well plates for 36 hours were serum-
deprived overnight and exposed to huFGF23 for 15 min-
utes, 1 hour, or 6 hours, depending on the experiment,
followed by Western blot analysis. For p-ERK detection,
blots were incubated with primary antibody (1:1,000
dilution) for 2 hours at room temperature, then secondary
horseradish peroxidase-conjugated antibody (1:4,000). The
signal was detected using enhanced chemiluminescence
(Amersham/GE Healthcare) and BIOMAX AR ﬁlm
(Sigma-Aldrich, St. Louis, MO). To detect total ERK on
the same blots, the blots were stripped with Western blot
stripping buffer (Pierce) for 15 minutes with shaking. Fil-
ters were blocked for 1 hour, followed by incubation with
primary antibody (1 hour) and secondary antibody (1 hour)
and developed.
Egr-1 Detection
PTECs were grown in 12-well plates for 48 hours, pre-
treated with serum-free medium for 2 hours, and treated
with huFGF23 overnight. Cell lysates were analyzed by
Western blot.
Phosphotyrosine Detection
PTECs were grown and pretreated as for p-ERK1/2 and
ERK1/2 and exposed to huFGF23 for 15 minutes, followed
by Western blot analysis. Lysates were incubated with
pTYR antibody (PY20).
Human FGF23R176Q
Both wild type FGF23 and huFGF23R176Q were expres-
sed in a Chinese hamster ovary (CHO) cell line. Cells were
transfected with Lipofectamine 2000 and selected in the
absence of HT. For protein production, cells were placed in
serum-free medium, and medium was harvested at 1 week.
Wild type FGF23 and huFGF23R176Q were puriﬁed by
cation exchange chromatography, followed by hydropho-
bic interaction chromatography (HIC). The puriﬁed protein
was formulated in PBS.
Soluble Murine Klotho
Soluble murine Klotho (1-982) 6X-His, comprising the
entire extracellular domain, was expressed in a CHO cell
line. Top clones were selected, and production was per-
formed under serum-free conditions for 7 days. Klotho was
puriﬁed by immobilized metal ion afﬁnity chromatography
(IMAC), followed by preparative size exclusion chroma-
tography (SEC) on S200 (GE Healthcare). Puriﬁed Klotho
was formulated in PBS.
CHO-Klotho ELK-1 Luciferase Reporter Cells
Full-length murine Klotho was stably expressed in a CHO
cell line. Klotho expression was enriched through FACS
sorting with an anti-Klotho antibody (R&D Systems,
AF1819). These cells were then transfected with the ELK-1
reporter luciferase reporter vector (Stratagene, Cedar
Creek, TX), serum-deprived overnight, and treated for 4
hours with huFGF23R176Q. Luciferase reporter activity
was assayed.
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MC3T3.E1 cells were cultured (2,500 cells/well in 96-well
plate or 12,500 cells/well in 24-well plate) in differentia-
tion medium—alpha-minimal essential medium (MEM)/
10% fetal bovine serum (FBS)/ascorbic acid (50 lg/mL)/
b-glycerolphosphate (BGP, 10 mM). Proliferation was
performed on day 4 cultures; alkaline phosphatase (ALP)
activity on day 7 cultures; and calcium accumulation, RNA
isolation, von Kossa, and ALP staining on day 14 cultures.
The day after plating, cells received fresh medium
supplemented with huFGF23R176Q (0.1–1,000 ng/mL),
murine Klotho (5, 50, and 500 ng/mL), combination of
huFGF23R176Q and Klotho, or FGF2 (100 ng/mL) as a
control. Culture medium with and without treatments
was replaced every 48 hours. For effects of FGFR
and MAPK pathway inhibitors for p38 (SB2035800),
P13K (LY294002), FGFR2(IIIc) neutralizing antibody
(MAB716), FGFR3 neutralizing antibody (MAB710),
MC3T3.E1/BF cells were grown and treated as above, then
exposed to the following: medium alone, medium/dime-
thysulfate (DMSO) vehicle control, Klotho (50 ng/mL),
huFGF23R176Q (1,000 ng/mL), Klotho (50 ng/mL) ?
huFGF23R176Q (1,000 ng/mL) with and without different
concentrations of inhibitors (ﬁve- or 10-fold dilutions)
ranging from 0.7 nM to 7 lM for p38 inhibitor (SB203580),
0.014 to 140 lM for PI3-kinase inhibitor (LY294002), 0.05
to 500 nM for FGFR2(IIIc) neutralizing antibody (MAB
716),0.2 nMto2lMforFGFR3 neutralizingantibody,0.65
nM to 6.5 lM for FGFR1 tyrosine kinase inhibitor
(SU5402), and 0.001 to 10 lM for ERK1/2 inhibitor
(UO126).
Proliferation Assay for MC3T3.E1 Cells
Proliferation was determined on day 4 growth phase cells
(FluoReporter Blue Fluorometric dsDNA Quantitation Kit,
Invitrogen). Brieﬂy, medium was replaced with distilled
water (100 lL) and cells were incubated at 37C for 1 hour
and lysed by freeze-thawing the plate. Hoechst dye mix
(100 lL) was added to each well, and contents were mixed
thoroughly. Fluorescence was measured at 360 nm for
excitation and at 460 nm for emission. Experiments were
performed at least six times.
Calcium Accumulation
On day 14, calcium accumulation (Stanbio Laboratories,
Boerne, TX) was determined by acid extraction and nor-
malized to total protein (Coomassie Plus Reagent, Pierce)
from the same well. Brieﬂy, after washing cells (10 mM
Tris–HCl, pH 7.4), 0.5 N HCl was added to wells, and the
plate was freeze-thawed three times to lyse cells. Plates
were shaken for 15 minutes to mix contents and then
centrifuged at 2,000 rpm at 4C to pellet debris. Calcium
content was determined by adding an aliquot of supernatant
to the o-Cresolphthalein Complexone-containing working
solution. The calcium-Cresolphthalein Complexone Com-
plex formed a fuchsia color, which was read at 575 nM.
The experiment was performed at least six times.
von Kossa Staining, ALP Staining, and ALP Activity
Mineral deposition was visualized by the von Kossa
staining method, which involved incubating cell layers in a
solution of silver nitrate (3%) under UV light for 30 min-
utes. ALP staining was performed by incubating cells for
30 minutes at 37C in Tris/glycine buffer (pH 8.4) con-
taining disodium naphthol AS-MX phosphate (Sigma) and
fast red TR salt (Sigma-Aldrich). After washing cell layers
(10 mM Tris, HCl [pH 7–8]), cells were supplemented with
glycine buffer (0.1 M glycine, 0.001 MgCl2 [pH 10.5]) and
frozen and thawed twice to obtain cell lysates to determine
ALP activity. Lysates were incubated with p-nitrophenyl
phosphate disodium hexahydrate (PNPP, Sigma-Aldrich)
solution for 30 minutes at 37C. Para-nitrophenol was
detected at 405 nM.
RNA Analysis
MC3T3.E1 cells were cultured as above in differentia-
tion medium supplemented with FGF23 (1,000 ng/mL),
Klotho (50 ng/mL), the combination huFGF23R176Q (1 or
1,000 ng/mL) ? Klotho (50 ng/mL), or FGF2 (100 ng/
mL) for 14 days. Total cellular RNA was isolated using
STAT 60 (Teltest, Friendswood, TX). RNA integrity was
conﬁrmed on a Bioanalyzer (Agilent Technologies, Palo
Alto, CA). B-DNA was performed on puriﬁed total cellular
RNA using the Quantigene Screen Kit (Genospectra, Fre-
mont, CA) following the manufacturer’s protocol (gene
panel 1: FGFR 1b, 1c, 2b, 2c, 3c, and 4; gene panel 2: ALP,
osteocalcin (OC), Runx2, type I collagen (a1) (COL1A1),
bone sialoprotein (IBSP), osteopontin (SPP1). The exper-
iment was performed two times.
Statistics
Statistical analyses were performed using GraphPad Prism
(GraphPad, San Diego, CA). Signiﬁcance was determined
by one-way analysis of variance (ANOVA) followed by
Dunnett’s post-test. All values represent mean ± standard
error of mean (SEM).
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FGF23 and Soluble Klotho Can Elicit Signaling
in Proximal Tubular Cells
To validate the functionality of human CHO-derived
huFGF23R176Q and murine soluble Klotho, we examined
the signaling response in a reporter cell, CHO-KL-ELK-1,
and a model FGF23-target cell, normal human PTECs. A
dose-dependent increase in luciferase activity in response
to huFGF23R176Q (EC50 1.60 ng/mL) was demonstrated
in CHO-KL-ELK-1 cells (Fig. 1a) but not CHO-KL cells
or parental CHO cells (not shown). In PTECs, which were
found to require exogenous OS-H or soluble Klotho for
signaling, both wild-type and huFGF23R176Q dose-
dependently increased p-ERK1/2 in the presence of OS-H
(4 lg/mL). Wild type and huFGF23R176Q increased
p-p38 and pTYR activity to a lesser extent (Fig. 1b, c).
HuFGF23R176Q induced greater activity than wild-type
FGF23, consistent with the increased stability of this
mutation found in ADHR patients. In PTECs, increased
p-ERK1/2 and pTYR activity were associated with
upregulation of Egr-1, a signaling molecule downstream of
FGF23 (Fig. 1d). In the presence of soluble Klotho (1 lg/
mL) and huFGF23R176Q (100 ng/mL), PTECs exhibited
enhanced p-ERK signaling comparedtohuFGF23R176Q ?
OS-H or Klotho alone (Fig. 2), conﬁrming the functionality
of murine soluble Klotho.
FGF23 and Soluble Klotho Inhibit Mineralization
in an Osteoblast Cell Line
To assess the effects of supraphysiological levels of serum
FGF23, as seen in CKD-MBD patients, on proliferation and
differentiation of osteoblastic cells, MC3T3.E1 cells were
exposed to huFGF23R176Q, Klotho, or their combination.
Abundant mineral was deposited over positive ALP-stained
nodular areas in cultures exposed to lower concentra-
tions (\100 ng/mL huFGF23R176Q ? 50 ng/mL Klotho);
however, exposure to higher concentrations (C100 ng/mL
huFGF23R176Q ? 50 ng/mL Klotho) led to complete
inhibitionofosteoblasticdifferentiation,asdemonstratedby
absence of red ALP staining and associated black mineral
deposits. Calcium quantiﬁcation conﬁrmed lack of mineral
deposition (Fig. 3). Neither huFGF23R176Q nor Klotho
exposure alone affected proliferation or calcium accumu-
lation. Proliferation was stimulated 2- to 2.5-fold by
FGF2 (Fig. 3a), which also inhibited mineral deposition
(Fig. 3b–e), consistent with reports of FGF2 actions on
osteoblastic cells in culture [27, 28]. Coadministration
ofhuFGF23R176QandKlotho,consistentlyanddose-depen-
dently, induced a low level of proliferation (maximum of
1.6-fold at 100 and 1,000 ng/mL huFGF23R176Q ?
50 ng/mL Klotho) associated with an inhibition of miner-
alization (Fig. 3). Consistent with the absence of minerali-
zation, the expression of osteoblast differentiation markers
ALP, OC, COL1A1, IBSP, and SPP1 was also downregu-
lated in MC3T3.E1 cultures exposed to huFGF23R176Q ?
Klotho (Fig. 4). Similar results were found for FGF2. Cells
exposedtohuFGF23R176QandOS-HorOS-Halonedidnot
survive (data not shown), consistent with the activities of
high levels of heparin on osteoblastic cells [29].
FGF23 and Soluble Klotho Signal Through FGFR1
and MAPK Pathway in MC3T3 Cells
To identify potential underlying mechanisms, we sought to
determine the FGFRs and signaling pathways involved in
the FGF23- and Klotho-induced effects on proliferation
and mineralization of MC3T3.E1 cells. MC3T3.E1 cells
preferentially expressed FGFR1(IIIc), FGFR2(IIIc), and
FGFR3(IIIc) isoforms, whereas the FGFR(IIIb) isoform and
FGFR4 were undetectable (Fig. 5a). HuFGF23R176Q ?
KlothotreatmentupregulatedFGFR1(IIIc)andFGFR3(IIIc)
anddownregulatedFGFR2(IIIc),whereasFGF2upregulated
FGFR1(IIIc) and downregulated both FGFR2(IIIc) and
FGFR3(IIIc) (Fig. 5b). Consistent with previous reports of
the absence of Klotho in bone cells [21], we did not detect
Klotho transcripts in rat bone sections by in situ hybridiza-
tion; however, Klotho transcripts were readily visible on
kidney distal tubules with antisense, but not sense, probes
(not shown). Further, we did not detect signiﬁcant Klotho
expression on the surface of MC3T3.E1 cells by FACS
analysis with anti-Klotho antibody (data not shown).
The huFGF23R176Q ? Klotho-induced suppression of
MC3T3.E1celldifferentiation,asmeasuredbyALPactivity,
was fully blocked by the FGFR1 inhibitor SU5402 (Fig. 6a)
and partially blocked by the MAPK pathway ERK1/2
inhibitor U0126 (Fig. 6b). In contrast, the p38 inhibitor
SB203580, the PI3K inhibitor LY294002, and FGFR2(IIIc)
and FGFR3 neutralizing antibodies were without effect
on the huFGF23R176Q ? Klotho-induced suppression of
MC3T3.E1 cell differentiation (data not shown).
Discussion
Supraphysiological levels of FGF23 in the presence of
soluble Klotho were associated with increased MC3T3.E1
cell proliferation and concomitant inhibition of minerali-
zation and bone cell marker gene expression in vitro. These
results support the hypothesis that elevated FGF23 found in
CKD-MBD patients may contribute to bone pathologies by
directly acting on bone cells, possibly in an autocrine/
paracrine manner.
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signaling via the MAPK pathway in normal human PTECs.
As reported for FGF23 and heparin in OK PTECs [26],
FGF23 led to phosphorylation of ERK and p38 in PTECs.
This phosphorylation was only observed in the presence of
OS-H, suggesting that high levels of FGF23 can signal in
PTECs in the absence of Klotho. Further supporting hep-
arin-mediated signaling, a previous report demonstrated
that BaF3 cells expressing FGFRs can respond to FGF23
with increased proliferation and decreased sodium phos-
phate transporter expression in the presence of OS-H [19].
The necessity for soluble Klotho and/or heparin in FGF23
signaling in PTECs was further demonstrated in our study
by the FGF23-induced ERK phosphorylation in the pres-
ence, but not the absence, of soluble Klotho. Although
recent studies have identiﬁed Klotho in proximal tubule
ﬂuid, urine, and PTECs [30], suggesting that FGF23 may
directly target PTEC membrane Klotho, we did not ﬁnd
any evidence to support the role of membrane Klotho.
However, the level of membrane Klotho in our PTEC
Fig. 1 a FGF23 dose response in CHO-KL and ELK-1 luciferase
reporter cells. Cells were serum-deprived overnight and exposed to
huFGF23R176Q for 4 hours. Luciferase reporter activity was assayed.
EC50 was 1.60 ng/mL. ***P\0.001 compared with FGF23 (0.1 ng/
mL). RLU, relative luminescent units. Values represent mean ±
SEM. b FGF23 signals in PTECs. Supraphysiological levels of
FGF23 and OS-H (4 lg/mL) increase p-ERK1/2 and p-p38 in human
PTECs in vitro. PTECs were plated at 2 9 10
6 cells per 24-well plate
and treated when\50% conﬂuent with EGF (10 ng/mL), human wild
type FGF23 or huFGF23R176Q (0–1,000 ng/mL) for 15 minutes,
and Western blot was performed for total, p-ERK1/2, and p-p38
expression. c Supraphysiological levels of FGF23 and OS-H (4 lg/
mL) increase tyrosine phosphorylation (pTYR) in human PTECs in
vitro. PTECs were exposed to human wild-type FGF23 and
huFGF23R176Q (1–1,000 ng/mL) for 15 minutes, followed by
Western blot analysis with pTYR antibody (PY20). d Supraphysio-
logical levels of huFGF23R176Q and OS-H (4 lg/mL) increase Egr-1
levels in human PTECs in vitro. PTECs were cultured in 12-well
plates for 48 hours and serum-deprived for 2 hours, followed by
exposure to huFGF23R176Q (0–1,000 ng/mL) in serum-free medium
overnight. Cell lysates were analyzed by Western blot
Fig. 2 Supraphysiological levels of FGF23 (100 ng/mL) and soluble
Klotho (1 lg/mL) activate p-ERK1/2 in human PTECs in vitro.
PTECs were cultured as above and exposed to control medium (PBS/
bovine serum albumin), huFGF23R176Q (100 ng/mL) and soluble
Klotho (1 lg/mL), huFGF23R176Q (100 ng/mL) ? OS-H (4 lg/mL),
PTH(1-34) (50 pM), and EGF (10 ng/mL) for 15 minutes, followed
by Western blot analysis
V. Shalhoub et al.: FGF23 and Klotho in MC3T3.E1 Cells 145
123cultures may have been below that needed for signaling,
requiring the addition of soluble Klotho. This would sup-
port a model in which renal distal tubules act as the pri-
mary source of secreted Klotho that targets PTECs [22].
Recently, FGF23 in serum of CKD-MBD dialysis
patients was found to be intact and active [17]. Thus, we
examined whether chronically elevated levels of FGF23 as
seen in CKD-MBD patients (100- to 10,000-fold above
Fig. 3 a FGF23 ? Klotho, not FGF23 or Klotho, inhibited calcium
accumulation in MC3T3.E1 cells. Cells were cultured in 96-well
plates at 2,500/well in differentiation medium (alpha-MEM/10%
FBS/ascorbic acid [50 lg/mL]/BGP [10 mM]) and supplemented
with huFGF23R176Q (F), murine Klotho (KL), their combination, or
FGF2 (basic FGF, bFGF) (100 ng/mL) for 14 days. Cell layers were
solubilized with 0.5 N HCl, and calcium content was quantiﬁed,
normalized to the total protein content in the same well, and
expressed as micrograms per milligram protein. b Calcium accumu-
lation per well (no normalization with protein). c Total protein per
well. d HuFGF23R176Q ? Klotho promoted a modest increase in
MC3T3.E1 cell proliferation. Proliferation assays were performed on
day 4 preconﬂuent cells. Bars represent mean ± SEM. *P\0.05,
**P\0.01, ***P\0.001 compared with differentiation medium
(Diff. Medium). e Dose-dependent inhibition of mineralization in the
presence of the high concentrations of huFGF23R176Q (100 and
1,000 ng/mL) and Klotho (5, 50, and 500 lg/mL). Cells were grown
as above on 24-well plates and stained for ALP or by the von Kossa
method to detect black mineral deposits. These results are represen-
tative of six experiments
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123normal values) could signal in extrarenal tissues such as
bone cells. We examined the direct effects of FGF23 on
osteoblastic MC3T3.E1 cell proliferation and differentia-
tion in vitro because studies in vivo may be hampered by
coexisting hormonal (e.g., PTH, vitamin D) and mineral
abnormalities that each have proven effects on bone cells.
Serum Klotho concentrations have been reported to be
approximately two- to threefold higher in healthy children
than adults (adult approximate mean 600 pg/mL) [31, 32].
Levels of serum Klotho in XLH children and adults were
no different from those in respective healthy individuals
[31]. In CKD patients, circulating serum Klotho levels are
yet to be reported, but acute kidney injury in humans and
rodent models was associated with decreased Klotho pro-
tein in blood, kidneys, and urine [33].
In mouse osteoblastic MC3T3.E1 cells soluble Klotho
appeared to confer speciﬁcity to endogenous osteoblastic
FGFRs for FGF23, as reported for other cells [21]. Sig-
naling in the presence of elevated FGF23 ? Klotho
increased proliferation slightly and inhibited mineralization
and bone marker gene expression. The ‘‘IIIc’’ forms
of FGFR1, FGFR2, and FGFR3 were preferentially
expressed in MC3T3.E1 cells; FGF23 ? Klotho upregu-
lated FGFR1(IIIc) and FGFR3(IIIc) and downregulated
FGFR2(IIIc). The expression proﬁle of FGFRs in
MC3T3.E1 cells parallels that found for rat calvarial cul-
tures and developing fetal mouse calvaria in that ‘‘IIIb’’
forms and FGFR4 were not expressed [25, 34]. To address
the molecular mechanisms associated with FGF23 action,
we examined canonical FGFR signal-transduction path-
ways as possible mediators of FGF23 action. The complete
rescue of ALP levels in the presence of FGFR1 inhibitor
SU5402 indicated that FGFR1 was the dominant receptor
through which FGF23 signals in MC3T3.E1 cells. This was
underscored by the lack of effect by FGFR2(IIIc) and
FGFR3 neutralizing antibodies on ALP levels. ALP
activity was partially restored by the MAPK pathway
ERK1/2 inhibitor U0126, indicating that additional path-
ways were likely involved. However, inhibitors for p38 or
PI3K could not rescue ALP inhibition induced by FGF23.
Fig. 4 Osteoblast marker mRNA expression was inhibited in
FGF23 ? Klotho-treated MC3T3.E1 cells (B-DNA analysis). Cells
were cultured in 12-well plates at 12,500/well in differentiation
medium (alpha-MEM/10% FBS/ascorbic acid [50 lg/mL]/BGP
[10 mM]) and supplemented with huFGF23R176Q (F) (1 and
1,000 ng/mL), murine Klotho (KL) (50 ng/mL), their combination,
or FGF2 (bFGF) for 14 days. Gene panel ALP, OC, Runx2/Cbfa1,
COL1A1, IBSP, and SPP1. Respective mRNA levels were normal-
ized to cyclophilin mRNA levels. Bars represent mean ± SEM.
*P\0.05, **P\0.01, ***P\0.001 compared with differentiation
medium (Diff. Medium)
Fig. 5 FGFRs were expressed and modulated by FGF23 ? Klotho,
but not Klotho or FGF23 alone (B-DNA analysis). Cells were cultured
in 12-well plates in differentiation medium (alpha-MEM/10% FBS/
ascorbic acid [50 lg/mL]/BGP [10 mM]) and supplemented with
huFGF23R176Q (F) (1 and 1,000 ng/mL), murine Klotho (KL)
(50 ng/mL), their combination, or FGF2 (bFGF) for 14 days. a FGFR
‘‘IIIc’’formsarepreferentiallyexpressedinMC3T3.E1cellsexposedto
differentiation medium alone. b FGFR1(IIIc). c FGFR2(IIIc).
d FGFR3(IIIc). Gene panel FGFR1(IIIb), FGFR1(IIIc), FGFR2(IIIb),
FGFR2(IIIc), FGFR3(IIIc) and FGFR4. Bars represent mean ± SEM.
*P\0.05, **P\0.01 compared with differentiation medium (Diff.
Medium)
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123The results with FGFR1 inhibitor SU5402 support those in
rat calvarial osteoblast cultures overexpressing FGF23 by
adenoviral delivery [25] and provide further support for
FGFR1 as the predominant FGF23 receptor in osteoblastic
cells. In the latter study, overexpression of FGF23 alone
inhibited calvarial osteoblast mineralization [25], whereas
here soluble Klotho was essential for FGF23-induced
inhibition of mineralization of MC3T3.E1 cells. The reason
for this is unknown but could be stage-speciﬁc, differential
expression of proteoglycans/heparins and/or related to dif-
ferent cell sources and culture methodologies [35]. In the
present study, elevated FGF23 actions appeared, in part, to
parallel FGF2 actions with lower potency. FGF2 is an
important regulator of osteoblast function and bone
formation. FGF2 stimulated proliferation, inhibited miner-
alization, and increased FGFR1(IIIc) expression, while
decreasing FGFR2(IIIc) and FGFR3(IIIc) expression. FGF2
has been reported to induce osteoblast proliferation and
differentiation in vitro, but the effects are stage-speciﬁc
[36].
Although exposure of MC3T3.E1 cells to soluble hep-
arin led to cell death in this study, FGF23 signaling in bone
cells may be stabilized by speciﬁc locally produced hepa-
rins, residing in the extracellular matrix, in the presence or
absence of soluble Klotho.
The concentrations of FGF23 used in this study include
those present in CKD-MBD patient serum. Normal serum
concentrations of FGF23 range 5–50 pg/mL, whereas in
CKD-MBD patients levels have been reported to range
from 100- to 10,000-fold normal [3, 4, 7]. Thus, 1 ng/mL is
20- to 200-fold normal levels, and 100 ng/mL is 2,000- to
20,000-fold normal levels.
Klotho-deﬁcient mice have elevated FGF23 levels
(2,000-fold levels found in wild-type mice) [21] but the
same phenotype as FGF23-deﬁcient mice [5], a ﬁnding that
does not support a pathological role for supraphysiological
FGF23 levels on nontarget tissues. However, Klotho-deﬁ-
cient animals survive for about 3 months [23], while CKD-
MBD patients are exposed to sustained high FGF23 levels
for years. In addition, Klotho-deﬁcient mice lack soluble
Klotho, which might be present in CKD-MBD patient
serum derived from tissues other than the kidneys.
In summary, FGF23/Klotho inhibited osteoblastic cell
mineralization and osteoblast marker gene expression,
likely via FGFR1 signaling. In addition, FGF23/Klotho
increased FGFR1(IIIc) and FGFR3(IIIc) expression in
MC3T3.E1 cells. Thus, in addition to affecting bone via
indirect phosphate wasting pathways, supraphysiological
FGF23 (and soluble Klotho) may directly impact bone in
diseases with sustained elevated FGF23 levels.
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